![Yuri Maricich](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Yuri Maricich
Teknisk/Vetenskaplig/F&U Direktör på
PEAR THERAPEUTICS, INC.
Förmögenhet: 43 508 $ per 2026-07-31
Profil
Yuri Maricich currently works at CAMP4 Therapeutics Corp., as Chief Medical Officer from 2023, Pear Therapeutics, Inc., as Chief Medical Officer & Head-Development, and Angelini Ventures SpA, as Advisor.
Dr. Maricich also formerly worked at Cavion LLC, as Chief Scientific Officer & Senior Medical Director from 2014 to 2016, Xdynia LLC, as President from 2011 to 2014, and Pear Therapeutics (US), Inc., as Chief Medical Officer & Head-Development from 2017 to 2023.
Dr. Maricich received his undergraduate degree from the University of Notre Dame, doctorate degree from the University of Washington, and Masters Business Admin degree from Harvard Business School.
Kända innehav i offentliga företag
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
| 2026-08-03 | 12 611 ( 0,02 % ) | 43 508 $ | 2026-07-31 |
Aktiva positioner av Yuri Maricich
| Företag | Position | Start |
|---|---|---|
| PEAR THERAPEUTICS, INC. | Teknisk/Vetenskaplig/F&U Direktör | - |
| CAMP4 THERAPEUTICS CORPORATION | Teknisk/Vetenskaplig/F&U Direktör | 2023-08-01 |
Angelini Ventures SpA
 Angelini Ventures SpA Investment ManagersFinance Angelini Ventures invests in companies located in North America, Europe, Israel and Italy. The firm focuses on digital healthcare, connected medical devices and life sciences. It participates in early stage capital requirements. | Konsult / Rådgivare | - |
Tidigare kända positioner av Yuri Maricich
| Företag | Position | Slut |
|---|---|---|
Pear Therapeutics (US), Inc.
 Pear Therapeutics (US), Inc. Packaged SoftwareTechnology Services Develops and provides a platform that combines pharmaceutical preparations with scientifically validated software applications | Teknisk/Vetenskaplig/F&U Direktör | 2023-01-01 |
Cavion LLC | Teknisk/Vetenskaplig/F&U Direktör | 2016-01-01 |
Xdynia LLC
 Xdynia LLC Pharmaceuticals: MajorHealth Technology Provides preclinical pharmaceutical services | President | 2014-01-01 |
Yuri Maricichs utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
53
Första gradens relationer
9
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 9 |
|---|---|
University of Notre Dame
 University of Notre Dame Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Xdynia LLC
Xdynia LLC Pharmaceuticals: MajorHealth Technology Provides preclinical pharmaceutical services | Health Technology |
Harvard Business School
 Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pear Therapeutics (US), Inc.
Pear Therapeutics (US), Inc. Packaged SoftwareTechnology Services Develops and provides a platform that combines pharmaceutical preparations with scientifically validated software applications | Technology Services |
Camp4 Therapeutics Corp.
 Camp4 Therapeutics Corp. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that engages in the development of regulatory RNA-based therapeutics | Health Technology |
Cavion LLC | |
Pear Therapeutics, Inc.
 Pear Therapeutics, Inc. Packaged SoftwareTechnology Services Operates as a commercial stage healthcare company that develops software based medicines | Technology Services |
Angelini Ventures SpA
Angelini Ventures SpA Investment ManagersFinance Angelini Ventures invests in companies located in North America, Europe, Israel and Italy. The firm focuses on digital healthcare, connected medical devices and life sciences. It participates in early stage capital requirements. | Finance |
